Cargando…

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells

BACKGROUND: Glioblastomas treated with temozolomide frequently develop resistance to pharmacological treatments. Therefore, there is a need to find alternative drug targets to reduce treatment resistance based on tumor dependencies. A possibility is to target simultaneously two proteins from differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro-Carrasco, Elena, Lazo, Pedro A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237761/
https://www.ncbi.nlm.nih.gov/pubmed/34195200
http://dx.doi.org/10.3389/fcell.2021.683038